key: cord-1033789-gqzspkgp
authors: Rodriguez-Sevilla, Juanjo; Rodó-Pin, Anna; Espallargas, Irene; Villar-García, Judit; Molina, Lluis; Terán, Purificación Pérez; Sanchez, Antonia Vázquez; Masclans, Joan Ramón; Jiménez, Carmen; Segovia, Raúl Millán; Zuccarino, Flavio; Salar, Antonio; Rodriguez-Chiaradía, Diego A
title: Pulmonary Embolism In Patients With Covid-19 Pneumonia: The Utility Of D-DIMER
date: 2020-07-15
journal: Arch Bronconeumol
DOI: 10.1016/j.arbres.2020.06.013
sha: 3351a524535b219aaf893d6ad19309de7bcfde34
doc_id: 1033789
cord_uid: gqzspkgp

nan

conditions including inflammation, cancer, pregnancy, trauma, and sepsis (1) . Ddimer is a useful rule-out test for avoiding imaging in several clinical settings(2).

In fact, in patients with low or intermediate clinical probability, D-dimer has negative predictive value to exclude deep vein thrombosis or PE without further testing in the outpatient setting(3). Nevertheless, its usefulness in hospitalized patients with suspected thromboembolism is less well established. Only few studies have evaluated the predictive value of quantification of D-dimers in hospitalized patients with PE (4), and there are no studies addressing this topic in patients with COVID-19. Thus, in the context of the COVID pandemic, in which seriously ill patients have respiratory symptoms, it is even more convenient to find an adequate value of D-dimer that can help when requesting imaging studies, such as computed tomography pulmonary angiography (CTPA).

A retrospective study was performed to analyse the predictive value of D-dimer to assess CTPA for diagnosis of PE in patients with COVID-19 pneumonia during their hospitalization. The local Clinical Research Ethical approved the study.

All patients included in current study were COVID-19 positive according to present diagnostic criterion (5) . They had undergone CTPA scans due to suspected PE and underwent D-dimer tests according guidelines (6) . D-dimers were checked at least at the time of admission and prior to CTPA. D-dimer (local reference range: <500 mcg/L FEU), was measured by a commercial latex- The current retrospective study identified that a D-dimer value of 2000 mcg/L was the best sensitivity cut-off point to rule out PE in patients with COVID-19 pneumonia. Besides, we recognized a D-dimer level of 30000 mcg/L as the best value of specificity to predict PE. Also, an increase of D-dimer of 4000 mcg/L from admission to the highest determination during hospitalization was found to be the best value to detect PE.

To our knowledge, this is the first report with the aim to identify specific D-dimer cut-off values in patients with COVID-19 pneumonia to predict PE. Several studies have shown that the risk of thrombotic events increases with rising Ddimer concentration in acutely ill-hospitalized patients (4, 8) . A recent study has demonstrated that despite systematic thrombosis prophylaxis, the incidence of It has been stated that viral infections could lead to a prothrombotic state. Dengue virus has been stated to give rise to increased Interleukin-6 (IL-6), which in turn leads to an increase in Plasminogen activator inhibitor-1 (PAI-1) (10) a decrease in tPA which leads to a pro-thrombotic state. Likewise, severe cases of COVID-19 and original SARS virus were associated with an increase IL-6 level (and other inflammatory markers) (11) , and elevated PAI-1 levels (12), respectively.

Our study presents several limitations: its retrospective nature and a sample size is small. These shortcomings are however counterbalanced by two strengths.

First, the wide range of D-dimer values both at admission and during hospitalization, second, 40% incidence when PE is suspected suggests a considerable frequent occurrence.

In conclusion, D-dimer monitoring helps in the evaluation of PE in patients with COVID-19 pneumonia and they should be considered in the clinical management of these patients. Our study opens the venue to future multicenter studies with a larger sample size for adequate validation.

ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the

Safety of excluding acute pulmonary embolism based on an unlikely clinical probability by the Wells rule and normal D-dimer concentration: a meta-analysis

D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial

Spanish Health Ministery Guidelines. Action procedure against cases of infection with the new coronavirus (SARS-CoV-2)

Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action

Diagnostic tests 2: Predictive values

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial

Incidence of thrombotic complications in critically ill ICU patients with

Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome

Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia

Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy